Cowen and Company reissued their hold rating on shares of Qiagen N.V. (NASDAQ:QGEN) in a report published on Thursday. They currently have a $33.00 target price on the stock.

QGEN has been the topic of a number of other reports. Deutsche Bank AG reaffirmed a buy rating on shares of Qiagen N.V. in a research note on Monday, July 31st. Barclays PLC reaffirmed an overweight rating and issued a $37.00 price target (up from $33.00) on shares of Qiagen N.V. in a research note on Monday, July 17th. BidaskClub downgraded shares of Qiagen N.V. from a buy rating to a hold rating in a research note on Wednesday, July 5th. Independent Research GmbH raised shares of Qiagen N.V. from a sell rating to a hold rating in a research note on Tuesday, August 1st. Finally, TheStreet raised shares of Qiagen N.V. from a c rating to a b rating in a research note on Monday, June 5th. Nine research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus price target of $33.17.

Qiagen N.V. (NASDAQ QGEN) traded up 0.19% during midday trading on Thursday, reaching $31.50. The company’s stock had a trading volume of 680,312 shares. The stock’s 50-day moving average price is $31.87 and its 200-day moving average price is $31.77. The firm has a market capitalization of $7.19 billion, a price-to-earnings ratio of 96.33 and a beta of 1.15. Qiagen N.V. has a 12 month low of $24.89 and a 12 month high of $35.26.

Qiagen N.V. (NASDAQ:QGEN) last posted its quarterly earnings results on Thursday, July 27th. The company reported $0.30 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.28 by $0.02. Qiagen N.V. had a net margin of 5.44% and a return on equity of 11.04%. The business had revenue of $349.00 million for the quarter, compared to the consensus estimate of $353.09 million. During the same period in the prior year, the business posted $0.24 earnings per share. Qiagen N.V.’s revenue for the quarter was up 4.4% compared to the same quarter last year. Analysts predict that Qiagen N.V. will post $1.21 EPS for the current year.

TRADEMARK VIOLATION WARNING: This report was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at https://www.watchlistnews.com/qiagen-n-v-s-qgen-hold-rating-reiterated-at-cowen-and-company/1601001.html.

Several large investors have recently modified their holdings of the company. Oppenheimer Asset Management Inc. grew its position in shares of Qiagen N.V. by 0.5% in the second quarter. Oppenheimer Asset Management Inc. now owns 3,961 shares of the company’s stock valued at $133,000 after purchasing an additional 20 shares during the last quarter. M&T Bank Corp grew its position in shares of Qiagen N.V. by 2.7% in the second quarter. M&T Bank Corp now owns 8,155 shares of the company’s stock valued at $273,000 after purchasing an additional 215 shares during the last quarter. Quadrant Capital Group LLC grew its position in shares of Qiagen N.V. by 4.1% in the second quarter. Quadrant Capital Group LLC now owns 5,742 shares of the company’s stock valued at $183,000 after purchasing an additional 225 shares during the last quarter. QS Investors LLC grew its position in shares of Qiagen N.V. by 1.7% in the second quarter. QS Investors LLC now owns 13,594 shares of the company’s stock valued at $456,000 after purchasing an additional 226 shares during the last quarter. Finally, Public Employees Retirement Association of Colorado grew its position in shares of Qiagen N.V. by 3.5% in the second quarter. Public Employees Retirement Association of Colorado now owns 7,214 shares of the company’s stock valued at $242,000 after purchasing an additional 246 shares during the last quarter. 63.01% of the stock is currently owned by institutional investors.

About Qiagen N.V.

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Analyst Recommendations for Qiagen N.V. (NASDAQ:QGEN)

Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.